Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

June 30, 2009

Study Completion Date

January 31, 2012

Conditions
Advanced CancerNon-Small Cell Lung Cancer
Interventions
DRUG

MKC-1

capsules, twice daily for 14 days in 21 day cycle

DRUG

pemetrexed

standard dosing of 500 mg/m2 infused every 21 days

Trial Locations (4)

46202

Indiana University Cancer Center, Indianapolis

52242

University of Iowa, Iowa City

53792

University of Wisconsin Hospital and Clinics, Madison

98122

Swedish Cancer Institute, Seattle

Sponsors
All Listed Sponsors
lead

CASI Pharmaceuticals, Inc.

INDUSTRY

NCT00408226 - Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter